Ivonescimab and short radiation for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have squamous cell esophageal cancer confirmed by biopsy.
- Your cancer must be advanced, come back after surgery, or have spread, and it has gotten worse on or you couldn't tolerate first-line treatment.
- You must have at least one tumor that can be measured on a scan.
- Your blood counts and organ function must meet certain minimum levels (like hemoglobin, white blood cells, liver and kidney tests).
- You must be between 18 and 80 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
This trial compares surgery versus a strong combination of chemotherapy and radiation for people with esophageal squamous cell carcinoma that has been treated first with immunotherapy. It aims to find which approach leads to better outcomes after the initial immunotherapy and chemotherapy.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
This trial tests a new drug called ivonescimab combined with chemotherapy, given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.